Recursion Pharmaceuticals Inc (RXRX)
8.26
-0.61
(-6.88%)
USD |
NASDAQ |
May 31, 16:00
8.36
+0.10
(+1.21%)
After-Hours: 20:00
Recursion Pharmaceuticals Cash from Operations (TTM): -316.76M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -316.76M |
December 31, 2023 | -287.78M |
September 30, 2023 | -258.45M |
June 30, 2023 | -240.07M |
March 31, 2023 | -234.23M |
December 31, 2022 | -83.52M |
September 30, 2022 | -99.93M |
Date | Value |
---|---|
June 30, 2022 | -78.44M |
March 31, 2022 | -50.47M |
December 31, 2021 | -158.61M |
September 30, 2021 | -88.88M |
June 30, 2021 | -75.29M |
March 31, 2021 | -58.34M |
December 31, 2020 | -45.40M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-316.76M
Minimum
Mar 2024
-45.40M
Maximum
Dec 2020
-148.30M
Average
-94.41M
Median
Cash from Operations (TTM) Benchmarks
Eli Lilly and Co | 3.676B |
Viking Therapeutics Inc | -54.87M |
Actinium Pharmaceuticals Inc | -39.63M |
Macrogenics Inc | -111.02M |
Marinus Pharmaceuticals Inc | -113.98M |